VistaGen Therapeutics (VTGN) Price/FCF Ratio: History & Chart

VistaGen Therapeutics, Inc.(VTGN)

Biotechnology · South San Francisco, CA

$0.25-0.01 (-3.95%)

Delayed quote: Oct 6, 2026, 3:10 PM EDT

About VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

South San Francisco, CA

41 employees

www.vistagen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shawn K. Singh

View full financials

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
VistaGen Therapeutics, Inc. (VTGN)	$11.22M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.25M	N/A	5.33	5.33	5.33
Phio Pharmaceuticals Corp. (PHIO)vs ›	$11.50M	N/A	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.13M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$11.12M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$11.09M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.08M	N/A	6.98	6.98	6.98
Caring Brands, Inc. (CABR)vs ›	$10.82M	N/A	N/A	N/A	N/A
Biofrontera Inc. (BFRI)vs ›	$11.93M	N/A	N/A	N/A	N/A
Pluri Inc. (PLUR)vs ›	$10.68M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

VistaGen Therapeutics, Inc. (VTGN)

$11.22M

N/A

Lisata Therapeutics, Inc. (LSTA)vs ›

$11.25M

N/A

5.33

Phio Pharmaceuticals Corp. (PHIO)vs ›